Evidence map›Paper›PMID 32856922›Full record

ArticleLangmuir : the ACS journal of surfaces and colloids2020

Evaluation of the In Vitro Stability of Stimuli-Sensitive Fatty Acid-Based Microparticles for the Treatment of Lung Cancer.

Paulina Dałek, Tomasz Borowik, Katarzyna Reczyńska, Elżbieta Pamuła, Wojciech Chrzanowski, Marek Langner

Open access · hybridAbstract read
In one paragraph

Article in Langmuir : the ACS journal of surfaces and colloids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Bioavailability by design - Vitamin DNanomedicine : nanotechnology, biology, and medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Paulina DałekDepartment of Biomedical Engineering, Wrocław University of Science and Technology, Wybrzeże Stanisława Wyspiańskiego 27, 51-270 Wrocław, Poland.ORCID 0000-0002-3554-5532
Tomasz BorowikLipotech Sp. Z o.o., Wadowicka 8A, 30-415 Kraków, Poland.
Katarzyna ReczyńskaFaculty of Materials Science and Ceramics, AGH University of Science and Technology, Aleja Adama Mickiewicza 30, 30-059 Kraków, Poland.
Elżbieta PamułaFaculty of Materials Science and Ceramics, AGH University of Science and Technology, Aleja Adama Mickiewicza 30, 30-059 Kraków, Poland.
Wojciech ChrzanowskiFaculty of Pharmacy, The University of Sydney, Pharmacy Building A15, Sydney, NSW 2006, Australia.
Marek LangnerDepartment of Biomedical Engineering, Wrocław University of Science and Technology, Wybrzeże Stanisława Wyspiańskiego 27, 51-270 Wrocław, Poland.
AGH University of Krakow · PLWrocław University of Science and Technology · PLThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fatty acid-based microparticles containing iron oxide nanoparticles and paclitaxel (PAX) are a viable proposition for the treatment of lung cancer. The microparticles inhaled as a dry powder can be guided to selected locations using an external magnetic field, and when accumulated there, the active compound release can be triggered by local hyperthermia. However, this general strategy requires that the active compound is released from microparticles and can reach the targeted cells before microparticles are removed. Isothermal titration calorimetry was used to demonstrate that the components of microparticles were released and transferred to albumins and lipid bilayers. The morphology of the measured particulates was studied with scanning electron microscopy and dynamic light scattering. To determine the cytotoxicity of microparticles, cell culture studies were done. It has been shown that the transfer efficiency depends predominantly on the fatty acid composition of microparticles, which, together with the active ingredient, accumulate predominantly in membrane structures after being released from microparticles and before entering the cytoplasm. The release process is sufficient; hence, paclitaxel-loaded microparticles effectively suppressed the proliferation of A549 human lung epithelial cells of malignant origin (IC

Indexed as

Fatty AcidsLung NeoplasmsA549 CellsDrug CarriersHumansMicroscopy, Electron, ScanningPaclitaxelParticle SizeDrug CarriersFatty AcidsPaclitaxel

Identifiers

PMID32856922
PMCPMC7513473
OpenAlexW3081723859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.